Literature DB >> 14749479

Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo.

Shoichiro Ohtani1, Shunsuke Kagawa, Yasuhisa Tango, Tatsuo Umeoka, Naoyuki Tokunaga, Yousuke Tsunemitsu, Jack A Roth, Yoichi Taya, Noriaki Tanaka, Toshiyoshi Fujiwara.   

Abstract

To analyze the mechanism of the antitumor effect of an adenoviral vector expressing the p53 tumor suppressor (Ad-p53) in vivo, we quantitatively assessed p53-targeted gene expression and visualized transcriptional activity of p53 in tumors in nude mice treated with Ad-p53. Human lung cancer (H1299) xenografts established in nude mice were treated by intratumoral administration of Ad-p53. The levels of expression of exogenous p53 and p53-targeted genes p21, MDM2, Noxa, and p53AIP1 were quantified by real-time reverse transcription-PCR (RT-PCR) and induction of apoptosis was observed histochemically on days 1-3, 7, and 14 after treatment. Expression of mRNA of exogenous p53 and p53-targeted genes (except p53AIP1) was at its maximum 1 day after Ad-p53 treatment and then decreased rapidly; apoptosis was evident in situ 2-3 days after treatment. We developed a noninvasive and simple method for monitoring the transcriptional activity of exogenous p53 following intratumoral administration of Ad-p53 in nude mice. We established H1299 cells that express the green fluorescent protein (GFP) reporter gene under the control of p53-responsive p21 promoter (i.e., the p53R-GFP reporter system). Xenografts of these cells in nude mice were treated by intratumoral administration of Ad-p53, and the transcriptional activity of exogenous p53 could be visualized as intratumoral GFP expression in real time by 3-CCD camera. Expression of GFP was maximal 3 days after treatment and decreased remarkably by 7 days after treatment. We demonstrated that Ad-p53 treatment rapidly induced p53-targeted genes and apoptosis in tumors and succeeded in visualizing p53 transcriptional activity in vivo. We also found that Ad-p53 infection induced phosphorylation of p53 at Ser(46) in p53-sensitive H1299 cells in vitro but not in p53-resistant H226Br cells, suggesting that phosphorylation of Ser(46) is involved in p53-dependent apoptosis. Our data indicate that quantitative analysis of p53-targeted gene expression by real-time quantitative RT-PCR and visualization of p53 transcriptional activity in fresh xenografts by using the p53R-GFP reporter system may be useful in assessing the mechanisms of the antitumor effects of Ad-p53 and novel therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14749479

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  5 in total

1.  MDM2: a novel mineralocorticoid-responsive gene involved in aldosterone-induced human vascular structural remodeling.

Authors:  Yasuhiro Nakamura; Saya Suzuki; Takashi Suzuki; Katsuhiko Ono; Ikumi Miura; Fumitoshi Satoh; Takuya Moriya; Haruo Saito; Shogo Yamada; Sadayoshi Ito; Hironobu Sasano
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 2.  High-dimensional single-cell cancer biology.

Authors:  Jonathan M Irish; Deon B Doxie
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

3.  Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy.

Authors:  Rodrigo Esaki Tamura; Rafael Bento da Silva Soares; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Cancer Biol Ther       Date:  2016-09-19       Impact factor: 4.742

4.  Homologous recombination-based adenovirus vector system for tumor cell-specific gene delivery.

Authors:  Qin Lu; Xun Ye; Fang Liu; Yi Zhao; Jie Qin; Min Liang; Chao Fang; Hong-Zhuan Chen
Journal:  Cancer Biol Ther       Date:  2013-06-12       Impact factor: 4.742

5.  Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells.

Authors:  Thomas Secher; Ascel Samba-Louaka; Eric Oswald; Jean-Philippe Nougayrède
Journal:  PLoS One       Date:  2013-10-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.